PHARMACOKINETICS (PK) OF HZN-825, A SMALL MOLECULE SELECTIVE ANTAGONIST OF LPAR1, AND THE EFFECT OF FOOD IN HEALTHY ADULT SUBJECTS

被引：0
|
作者：
Song, Y. [1 ]
Ali, F. [2 ]
Ye, Z. [2 ]
Zarzoso, J. [1 ]
Rogowski, J. [1 ]
Sun, Y. [1 ]
Xin, Y. [1 ]
机构：
[1] Horizon Therapeut, San Francisco, CA USA
[2] Horizon Therapeut, Chicago, IL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-071
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [31] Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel oral small molecule GLP-1 receptor agonist (HRS-7535) in healthy subjects
    Wu, J.
    Hu, W.
    Du, Y.
    Zhang, Q.
    Zhou, R.
    Zhang, Q.
    Qin, H.
    Ye, Z.
    Xu, Y.
    Feng, S.
    Shu, C.
    Shen, Y.
    Fan, Y.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S316 - S317
  • [32] Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study
    Prokopienko, Alexander J.
    Wang, Junyao
    Yajnik, Vijay
    Baratta, Mike
    Desai, Nirav K.
    Richmond, Camilla A.
    Suri, Ajit
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (02): : 217 - 225
  • [33] A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
    Shimizu, Ryosuke
    Sonoyama, Takuhiro
    Fukuhara, Takahiro
    Kuwata, Aya
    Matsuo, Yumiko
    Kubota, Ryuji
    CLINICAL DRUG INVESTIGATION, 2023, 43 (10) : 785 - 797
  • [34] A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
    Ryosuke Shimizu
    Takuhiro Sonoyama
    Takahiro Fukuhara
    Aya Kuwata
    Yumiko Matsuo
    Ryuji Kubota
    Clinical Drug Investigation, 2023, 43 : 785 - 797
  • [35] Cyclosporine has no clinically meaningful effect on pharmacokinetics (PK) of BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in healthy subjects
    Chimalakonda, A.
    Jones, J., III
    Dockens, R.
    Throup, J.
    Banerjee, S.
    Girgis, I.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S277 - S278
  • [36] Pharmacokinetics (PK), Safety, and Tolerability of Multiple Ascending Doses of the Cannabinoid CB1 (CB1) Receptor Antagonist CP-945,598 in Healthy Overweight and Obese Subjects
    Cronenberger, Carol
    Dvorak, Roman
    Venkatakrishnan, Karthik
    Checchio, Tina
    Manganello, Jeanne
    Fountaine, Robert
    Obourn, John
    OBESITY, 2008, 16 : S140 - S140
  • [37] PHARMACOKINETICS (PK) AND SAFETY OF OLORINAB (APD371), A HIGHLY SELECTIVE, PERIPHERALLY ACTING FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), IN HEALTHY ADULT SUBJECTS.
    Stauber, K.
    Oh, D.
    Tang, Y.
    Lindstrom, B.
    English, B.
    Cabell, C.
    Ruckle, J.
    Searle, S.
    Kam, J.
    Jones, R.
    Grundy, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S79 - S79
  • [38] Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects
    Schueller, Olivier
    McDermott, John
    Evans, Phil
    Lohmer, Lauren
    Alabanza, Anginelle
    Patel, Jeegar
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (07): : 807 - 814
  • [39] Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects
    Berger, Benjamin
    Kaufmann, Priska
    Koch, Annelize
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 931 - 941
  • [40] TOLERABILITY, SAFETY AND PHARMACOKINETICS OF SINGLE-DOSE AND MULTIPLE DOSING OF THE SELECTIVE D1 ANTAGONIST NNC-01-0687 IN HEALTHY-SUBJECTS
    SKRUMSAGER, BK
    CHRISTENSEN, JV
    SNEL, S
    SEIBERLING, M
    PSYCHOPHARMACOLOGY, 1995, 121 (03) : 294 - 299
12345